Search

Displaying results 5261 - 5270 of 5449 in total
  1. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    TM5614 inhibition of PAI-1, specifically, downregulates PCSK9 at the transcriptional level[A228793].

  2. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039.

  3. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  4. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

    Products: Zenapax 5mg/ml
  5. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    [A259966] Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h.

  6. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].

  7. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.

  8. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

  9. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein.

  10. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    It is currently not approved in the USA.